TB Alliance

TB Alliance and Lupin announce commercial partnership for new therapy for highly drug-resistant TB

Agreement between non-profit product development partnership and multinational pharmaceutical company will expand access to new TB drug.

Read More →

TB Alliance: Community engagement virtual forum - recording now available online

On 12 August 2021, TB Alliance hosted a public webinar for community stakeholders to share details of the recently announced results from the ZeNix Phase 3 clinical trial. The trial revealed that the 6-month BPaL treatment regimen (bedaquiline, pretomanid and linezolid) remains effective against highly drug-resistant strains of TB with either reduced dosage or duration of the linezolid component of the regimen. Simultaneously, with the maintenance of efficacy, there was a decrease in linezolid associated side effects.

Read More →

TB Alliance: Community engagement virtual forum

On 12 August 2021, TB Alliance will host a public webinar for community stakeholders to share details of the recently announced results from the ZeNix Phase 3 clinical trial. The trial revealed that the 6-month BPaL treatment regimen (bedaquiline, pretomanid and linezolid) remains effective against highly drug-resistant strains of TB with either reduced dosage or duration of the linezolid component of the regimen. Simultaneously, with the maintenance of efficacy, there was a decrease in linezolid associated side effects.

Read More →

Dashboard: Access to the BPaL regimen

TB Alliance launched a webpage to provide information on national-level access to the BPaL regimen - a three-drug, 6-month, all-oral regimen composed of bedaquiline, pretomanid and linezolid for the treatment of highly drug-resistant forms of TB.

Read More →

Publication: Results of the acceptability and feasibility study of the BPaL regimen

TB Alliance and KNCV Tuberculosis Foundation published a study in BMC Public Health, focused on collecting stakeholder views (in Nigeria, Indonesia, and Kyrgyzstan) regarding the acceptability, feasibility, and likelihood of stakeholders implementing the BPaL regimen. BPal is a three-drug, 6-month, all-oral regimen composed of bedaquiline, pretomanid and linezolid for the treatment of highly drug-resistant forms of TB.

Read More →

Launch of UNITE4TB partnership marks a new era in TB treatment development

The partnership will accelerate the development of new TB drug regimens as part of the Innovative Medicines Initiative (IMI), a public-private European Research & Development Consortium.

Read More →

ZeNix trial results show effectiveness of regimen against highly drug-resistant TB

The results of ZeNix, a Phase 3 clinical trial that took place in 11 sites across Georgia, Moldova, Russia, and South Africa, revealed that the 6-month BPaL treatment regimen (bedaquiline, pretomanid and linezolid) remains effective against highly drug-resistant strains of TB with either reduced dosage or duration of the linezolid component of the regimen. Simultaneously, with the maintenance of efficacy, there was a decrease in linezolid associated side effects.

Read More →

A persistent shortfall in TB research and development funding

NEW YORK (April 15, 2021) — The 2020 G-Finder Report, released today, shows that low funding levels are putting life-saving science—and especially the most vulnerable—at risk. Global investments in tuberculosis (TB) research and development (R&D) funding totaled of $670 million in 2019. This is far short of the estimated $2.16 billion that the Stop TB Partnership estimates is needed annually to develop and deliver new tools that can end the TB pandemic, which causes illness in 10 million people each year. These tools include effective vaccines, diagnostics and drug regimens.

Read More →

Astellas and TB Alliance enter into a new collaborative research agreement to identify lead compounds for the treatment of TB

TOKYO and NEW YORK (March 31, 2021) — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and TB Alliance (President and CEO: Mel Spigelman, M.D.), a non-profit organization dedicated to finding faster-acting and affordable drug regimens to fight tuberculosis (TB) today announced that they have entered into a new collaborative research (“Hit-to-Lead PJ”) agreement to identify lead compounds for the treatment of TB.

Read More →

STAND clinical trial results published

March 25, 2021 – Results of TB Alliance’s Phase 3 clinical trial, known as STAND, have been published in the International Journal of Tuberculosis and Lung Disease.

Read More →

Page 1 of 10 · Total posts: 10

1 2 Last→